COPD in chronic heart failure: Less common than previously thought?

Heart and Lung: Journal of Acute and Critical Care

Volumn 42, Issue 5, 2013, Pages 365-371

  Minasian, Armine G ^a   van den Elshout, Frank J J ^a   Dekhuijzen, P N Richard ^b   Vos, Petra J E ^a   Willems, Frank F ^a   van den Bergh, Paul J P C ^a   Heijdra, Yvonne F ^b  

^a RIJNSTATE HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chronic heart failure; Chronic obstructive pulmonary disease; Fixed ratio; Lower limit of normal; Prevalence

Indexed keywords

TIOTROPIUM BROMIDE;

AGED; AIRWAY OBSTRUCTION; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LUNG CONGESTION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SPIROMETRY;

EID: 84883233180     PISSN: 01479563     EISSN: 15273288     Source Type: Journal    
DOI: 10.1016/j.hrtlng.2013.07.002     Document Type: Article

References (50)

1. Hawkins N.M., Petrie M.C., Jhund P.S., Chalmers G.W., Dunn F.G., McMurray J.J. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009, 11:130-139.
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHBLI/WHO workshop report. Available at: ;2011. http://www.goldcopd.org.
3. Iversen K.K., Kjaergaard J., Akkan D., et al. Chronic obstructive pulmonary disease in patients admitted with heart failure. JIntern Med 2008, 264:361-369.
4. Mascarenhas J., Lourenco P., Lopes R., Azevedo A., Bettencourt P. Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. Am Heart J 2008, 155:521-525.
5. Macchia A., Rodriguez Moncalvo J.J., Kleinert M., et al. Unrecognised ventricular dysfunction in COPD. Eur Respir J 2012, 39:51-58.
6. Boschetto P., Fucili A., Stendardo M., et al. Occurrence and impact of chronic obstructive pulmonary disease in elderly patients with stable heart failure. Respirology 2013, 18:125-130.
7. Steinacher R., Parissis J.T., Strohmer B., et al. Comparison between ATS/ERS age- and gender-adjusted criteria and GOLD criteria for the detection of irreversible airway obstruction in chronic heart failure. Clin Res Cardiol 2012, 101:637-645.
8. Quanjer P.H., Enright P.L., Miller M.R., et al. Open letter: the need to change the method for defining mild airway obstruction. Prim Care Respir J 2010, 19:288-291.
9. Celli B.R., Halbert R.J. Point: should we abandon FEV/FVC < 0.70 to detect airway obstruction? No. Chest 2010, 138:1037-1040.
10. Enright P., Brusasco V. Counterpoint: should we abandon FEV/FVC < 0.70 to detect airway obstruction? Yes. Chest 2010, 138:1040-1042. [discussion 42-44].
11. Townsend M.C. Conflicting definitions of airways obstruction: drawing the line between normal and abnormal. Chest 2007, 131:335-336.
12. Garcia-Rio F., Soriano J.B., Miravitlles M., et al. Overdiagnosing subjects with COPD using the 0.7 fixed ratio: correlation with a poor health-related quality of life. Chest 2011, 139:1072-1080.
13. Hansen J.E., Sun X.G., Wasserman K. Spirometric criteria for airway obstruction: use percentage of FEV1/FVC ratio below the fifth percentile, not < 70%. Chest 2007, 131:349-355.
14. Hardie J.A., Buist A.S., Vollmer W.M., Ellingsen I., Bakke P.S., Morkve O. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 2002, 20:1117-1122.
15. Hnizdo E., Glindmeyer H.W., Petsonk E.L., Enright P., Buist A.S. Case definitions for chronic obstructive pulmonary disease. COPD 2006, 3:95-100.
16. Miller M.R., Quanjer P.H., Swanney M.P., Ruppel G., Enright P.L. Interpreting lung function data using 80 percent of predicted and fixed thresholds misclassifies over 20% of patients. Chest 2011, 139:52-59.
17. Roberts S.D., Farber M.O., Knox K.S., et al. FEV1/FVC ratio of 70% misclassifies patients with obstruction at the extremes of age. Chest 2006, 130:200-206.
18. Swanney M.P., Ruppel G., Enright P.L., et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax 2008, 63:1046-1051.
19. Schermer T.R., Smeele I.J., Thoonen B.P., et al. Current clinical guideline definitions of airflow obstruction and COPD overdiagnosis in primary care. Eur Respir J 2008, 32:945-952.
20. Cerveri I., Corsico A.G., Accordini S., et al. Underestimation of airflow obstruction among young adults using FEV1/FVC <70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes. Thorax 2008, 63:1040-1045.
21. Pellegrino R., Viegi G., Brusasco V., et al. Interpretative strategies for lung function tests. Eur Respir J 2005, 26:948-968.
22. Dickstein K., Cohen-Solal A., Filippatos G., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008, 29:2388-2442.
23. Hawkins N.M., Petrie M.C., Macdonald M.R., et al. Heart failure and chronic obstructive pulmonary disease the quandary of beta-blockers and beta-agonists. JAm Coll Cardiol 2011, 57:2127-2138.
24. Egred M., Shaw S., Mohammad B., Waitt P., Rodrigues E. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM 2005, 98:493-497.
25. Celli B.R., Halbert R.J., Isonaka S., Schau B. Population impact of different definitions of airway obstruction. Eur Respir J 2003, 22:268-273.
26. Glaser S., Schaper C., Obst A., et al. Impact of different definitions of airflow limitation on the prevalence of chronic obstructive pulmonary disease in the general population. Respiration 2010, 80:292-300.
27. Lindberg A., Jonsson A.C., Ronmark E., Lundgren R., Larsson L.G., Lundback B. Prevalence of chronic obstructive pulmonary disease according to BTS, ERS, GOLD and ATS criteria in relation to doctor's diagnosis, symptoms, age, gender, and smoking habits. Respiration 2005, 72:471-479.
28. Shirtcliffe P., Weatherall M., Marsh S., et al. COPD prevalence in a random population survey: a matter of definition. Eur Respir J 2007, 30:232-239.
29. Vollmer W.M., Gislason T., Burney P., et al. Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study. Eur Respir J 2009, 34:588-597.
30. Viegi G., Pedreschi M., Pistelli F., et al. Prevalence of airways obstruction in a general population: European Respiratory Society vs American Thoracic Society definition. Chest 2000, 117:339S-345S.
31. O'Hanlon R., O'Shea P., Ledwidge M., et al. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. JCard Fail 2007, 13:50-55.
32. Borg G.A. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982, 14:377-381.
33. Quanjer P.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., Yernault J.C. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993, 16:5-40.
34. http://www.fk.cvz.nl/.
35. Salpeter S.R., Ormiston T.M., Salpeter E.E. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004, 125:2309-2321.
36. Maak C.A., Tabas J.A., McClintock D.E. Should acute treatment with inhaled beta agonists be withheld from patients with dyspnea who may have heart failure?. JEmerg Med 2011, 40:135-145.
37. Singh S., Loke Y.K., Furberg C.D. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008, 300:1439-1450.
38. Salpeter S.R. Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events?: a synthesis of the available evidence. Drugs 2009, 69:2025-2033.
39. Michele T.M., Pinheiro S., Iyasu S. The safety of tiotropium - the FDA's conclusions. NEngl J Med 2010, 363:1097-1099.
40. Mannino D.M., Diaz-Guzman E. Interpreting lung function data using 80% predicted and fixed thresholds identifies patients at increased risk of mortality. Chest 2012, 141:73-80.
41. Mannino D.M., Sonia Buist A., Vollmer W.M. Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function?. Thorax 2007, 62:237-241.
42. Izquierdo Alonso J.L., De Lucas Ramos P., Rodriguez Glez-Moro J.M. The use of the lower limit of normal as a criterion for COPD excludes patients with increased morbidity and high consumption of health-care resources. Arch Bronconeumol 2012, 48:223-228.
43. Akkermans R.P., Berrevoets M.A., Smeele I.J., et al. Lung function decline in relation to diagnostic criteria for airflow obstruction in respiratory symptomatic subjects. BMC Pulm Med 2012, 12:12.
44. Guder G., Brenner S., Angermann C.E., et al. GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study. Respir Res 2012, 13:13.
45. Brusasco V. Spirometric definition of COPD: exercise in futility or factual debate?. Thorax 2012, 67:569-570.
46. Lamprecht B., Schirnhofer L., Kaiser B., Buist S.A., Mannino D.M., Studnicka M. Subjects with discordant airways obstruction: lost between spirometric definitions of COPD. Pulm Med 2011, 2011:780215.
47. Mohamed Hoesein F.A., Zanen P., Sachs A.P., Verheij T.J., Lammers J.W., Broekhuizen B.D. Spirometric thresholds for diagnosing COPD: 0.70 or LLN, pre- or post-dilator values?. COPD 2012, 9:338-343.
48. Mohamed Hoesein F.A., Zanen P., Lammers J.W. Lower limit of normal or FEV(1)/FVC <0.70 in diagnosing COPD: an evidence-based review. Respir Med 2011, 105:907-915.
49. Hankinson J.L., Odencrantz J.R., Fedan K.B. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999, 159:179-187.
50. Quanjer P.H., Stanojevic S., Cole T.J., et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 2012, 40:1324-1343.